Date: 2015-11-17
Type of information: Establishment of a new subsidiary in the US
Compound: Biophytis Inc
Company: Biophytis (France)
Therapeutic area: Metabolic diseases - Neurodegenerative diseases - Ophtalmological diseases
Type agreement: establishment of a new subsidiary in the US
Action mechanism:
Disease:
Details: * On November 17, 2015, Biophytis, an emerging geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), announced the creation of Biophytis Inc, a new subsidiary in Cambridge, Massachusetts. The early opening, initially planned for the first half of 2016, will facilitate clinical development of the companies mid-stage clinical development program, Sarcob to treat sarcopenic obesity and Maculia to treat dry AMD.
Sarcob are orally available selective MAS receptor agonists, which have demonstrated preclinical proof of concept for sarcopenic
obesity and satisfactory safety and tolerability in clinical Phase I testing. The the lead drug-candidate in the Sarcob program, BIO
101, is scheduled to enter Phase IIb clinical trials in mid-2016.
Financial terms:
Latest news:
